WGRX
Wellgistics Health, Inc. Common StockWGRX
WGRX
About: Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
–
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for WGRX.
Financial journalist opinion
Based on 6 articles about WGRX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure
TAMPA, FL, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (the “Company”), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that Tim Canning, Chief Executive Officer, will be departing the company. Mr. Canning's leadership tenure helped guide Wellgistics Health through pivotal phases, and the Company expresses gratitude for his contributions.
Neutral
GlobeNewsWire
1 week ago
Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond ™ , is designed to provide multiple levels of protection
Neutral
GlobeNewsWire
2 weeks ago
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo's emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo's first marketed product is Galectovid™, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Further details on Galectovid™ are available at www.galectovid.com .
Neutral
GlobeNewsWire
2 weeks ago
Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering
Tampa, Florida, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 shares of its common stock at a public offering price of $4.50 per share. The shares have been approved for listing on the Nasdaq Capital Market and commenced trading on February 21, 2025, under the ticker symbol "WGRX."
Neutral
Seeking Alpha
2 weeks ago
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.
Neutral
GlobeNewsWire
3 weeks ago
Wellgistics Health, Inc. Announces Pricing of $4.0 Million Initial Public Offering
Tampa, Florida, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the pricing of its initial public offering (the "Offering") of 888,889 ordinary shares at a public offering price of $4.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on February 21, 2025, under the ticker symbol "WGRX."
Charts implemented using Lightweight Charts™